CRS联合顺铂腹腔热灌注化疗治疗卵巢癌的近远期效果观察  

Short-term and long-term effects of CRS combined with cisplatin in the treatment of ovarian cancer

作　　者：宋敏[1] Song Min(Department of Gynecology,Linyi Traditional Chinese Medicine Hospital,Shandong Province,Linyi,Shandong,276000,China)

机构地区：[1]山东省临沂市中医医院妇科,山东临沂276000

出　　处：《当代医学》2020年第19期114-116,共3页Contemporary Medicine

摘　　要：目的探讨肿瘤细胞减灭术(CRS)联合顺铂腹腔热灌注化疗(HIPEC)治疗卵巢癌的近远期效果。方法选取本院2013年1月至2018年1月收治的60例卵巢癌患者作为研究对象,按照治疗方法不同分成对照组与研究组,各30例。对照组采用CRS+术后辅助全身静脉化疗治疗,研究组则采用CRS+顺铂HIPEC+全身静脉化疗治疗,比较两组近期疗效和不良反应,并随访1年观察患者的生存率。结果研究组患者近期临床疗效为90.00%,明显高于对照组的66.66%(P<0.05)。研究组患者Ⅲ~Ⅳ级(即严重不良反应)化疗不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。随访1年后,研究组患者在1年内的生存率为93.33%,高于对照组的63.33%(P<0.05)。结论肿瘤细胞减灭术联合顺铂腹腔热灌注化疗治疗卵巢癌,可有效延长中晚期卵巢癌患者的无疾病进展时间,减轻不良反应,提高患者的生存率,值得在临床上进行深入研究和推广。Objective To investigate the short-term and long-term effects of cytoreductive surgery(CRS)combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy(HIPEC)in the treatment of ovarian cancer.Methods 60 patients with ovarian cancer admitted to our hospital from January 2013 to January 2018 were selected as study subjects.All patients were divided into control group and study group according to different treatment methods,with 30 cases in each group.The control group were treated with CRS+postoperative adjuvant systemic chemotherapy,while 30 patients in the study group were treated with CRS+cisplatin HIPEC+systemic intravenous chemotherapy.The short-term efficacy and adverse reactions were compared between the two groups,and the survival rate was observed after 1 year of follow-up.Results The short-term clinical efficacy(90.00%)of the study group was significantly higher than that of the control group(66.66%)(P<0.05).The incidence of chemotherapy adverse reactions in gradeⅢ-Ⅳ(ie serious adverse reactions)in the study group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).After 1 year of follow-up,the survival rate of the study group was 93.33%in 1 year,which was higherthan that of the control group(63.33%)(P<0.05).Conclusion Tumor cytoreductive surgery combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy for ovarian cancer can effectively prolong the progression of disease progression in patients with advanced ovarian cancer,reduce adverse reactions and improve the survival rate of patients.It is worthy of in-depth research and promotion in clinical practice.

关 键 词：肿瘤细胞减灭术 顺铂 腹腔热灌注化疗 静脉化疗 不良反应 生存率 

分 类 号：R737.31[医药卫生—肿瘤]